Navigation Links
BellBrook Labs Launches Ultra-Sensitive Methyltransferase Assay to Accelerate Epigenetic Drug Discovery
Date:8/10/2017

BellBrook Labs announces the launch of their latest drug discovery tool, the AptaFluor SAH Methyltransferase Assay, an enabling new high throughput screening (HTS) assay to aid researchers in their search for breakthrough drugs targeting epigenetic pathways that drive cancer and other debilitating diseases.

Chemical modification of gene expression, also known as epigenetics, is perhaps the most promising area for molecularly targeted drug discovery since validation of kinases as drug targets. Methyltransferases are the largest class of epigenetic enzymes, and several have been shown to play a causative role in cancer and other diseases. Several years ago, major drug discovery efforts were initiated using HTS to identify methyltransferase inhibitors, much like the successful approach used for protein kinases. However, due to their intrinsic properties, detection of methyltransferase activity requires extremely sensitive radioactive assays and/or large amounts of methyltransferase enzymes, which made HTS impractical in many instances. For these reasons, there has been a long-standing need for more sensitive, non-radioactive assays to enable robust, cost effective screening of methyltransferase targets.

As a first-of-its-kind homogeneous assay using aptamers (nucleic acid-based affinity reagents) for HTS, the AptaFluor SAH Methyltransferase Assay provides an elegant solution to the cost and sensitivity barriers that were hampering the discovery of methyltransferase inhibitors. Methyltransferases produce a variety of methylated products, but all use S-adenosylmethionine (SAM) as the methyl donor, leaving S-adenosylhomocysteine (SAH) as a common reaction product. The AptaFluor SAH Assay is based on a naturally occurring microbial aptamer, discovered by Yale University professor Ron Breaker, which evolved to recognize SAH with exquisite sensitivity and selectivity.

BellBrook scientists engineered the SAH aptamer to produce a fluorescent signal on binding to SAH, resulting in a non-radioactive assay with unparalleled sensitivity. By directly detecting SAH, the new AptaFluor assay is universal, allowing the researcher to use the assay for virtually any methyltransferase enzyme. The assay utilizes a simple mix-and-read format with a far red positive TR-FRET readout, ensuring its compatibility with automated dispensing equipment and plate readers commonly used for HTS. With this novel assay technology, scientists can now more easily study challenging methyltransferase targets with the efficiency demanded by today’s drug discovery programs.

About BellBrook Labs

BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions. BellBrooks core technology Transcreener® is a universal, homogeneous biochemical assay platform based on detection of nucleotides that makes it easy to screen thousands of different enzymes. These include validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. Detection reagents and drug discovery services from BellBrook Labs help researchers progress toward more effective therapies for cancer and other debilitating diseases.

Read the full story at http://www.prweb.com/releases/New-Methyltransferase/HTS-Assay/prweb14582831.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. BellBrook Labs Expands Drug Discovery Services Portfolio to Include Lead Discovery Services
2. BellBrook Labs Webinar on July 22nd: Simplifying HTS with Orthogonal Pooled Screening
3. BellBrook Labs Teams Up with UW-Madison to Fight Neurodegenerative Diseases using Stem Cells and Microfluidics
4. BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay
5. BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening
6. BellBrook Labs Webinar: Transcreener® HTS assays for UDP, GDP, and CMP as a Universal Glycosyltransferase Assay Platform
7. BellBrook Labs and UW-Madison Team Awarded NCI Contract to Develop Next Generation Cancer Models
8. BellBrook Labs Develops a TR-FRET Based Transcreener GTPase Assay
9. BellBrook Labs Seeking Partners to Accelerate Commercialization of Innovative HTS Assay Technologies
10. BellBrook Labs Launches New Turn Key Methyltransferase Assay Kit for Oncogenic Histone Methyltransferase EZH2
11. BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... representations of a complex biological network, a depiction of a system of linkages ... said Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
Breaking Biology Technology:
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):